EpicentRx To Present at International Symposium on the Neuroprotective Effects of RRx-001 in Alzheimer’s and Parkinson’s diseases in Multiple Disease Models

by EpicentRx | Mar 28, 2023 | 2023, Press Releases

TORREY PINES, Calif., March 28, 2023 — EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, has been selected for a symposium presentation at AD/PD 2023, an International Conference on Alzheimer’s & Parkinson’s...

How (Not) to Speak Australian

by EpicentRx | Mar 23, 2023 | Blog

G’day, mate. In case you didn’t know, that’s Australian for good day, friend. However, to our untrained ears, as Americans, it sounds like, “good eye might.” More like “good ear might” since we’re talking about Australian accents. In the 1980s, Foster’s drink company...

Profile EpicentRx, Inc

by EpicentRx | Mar 21, 2023 | Media

Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs

by EpicentRx | Mar 21, 2023 | 2023, Press Releases

RRx-001 is a small molecule direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegeneration, and other inflammatory conditions RRx-001 is the most advanced direct NLRP3 inflammasome inhibitor in clinical development, having been evaluated in over 300...

Spotlight on Elena Prokopenko

by EpicentRx | Mar 20, 2023 | Meet The Team

Elena’s preferences (lightning round) Quality vs quantity? “Quality of course” Chicken wings or Chicken Kyiv? “Chicken wings” San Diego or Chicago? “San Diego” EpicentRx or anywhere else? “EpicentRx. By far. No other...